Cover Image
市場調查報告書

轉化生長因子-β1 (TGFB1) :開發中產品分析

Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 368726
出版日期 內容資訊 英文 75 Pages
訂單完成後即時交付
價格
Back to Top
轉化生長因子-β1 (TGFB1) :開發中產品分析 Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2016
出版日期: 2016年07月30日 內容資訊: 英文 75 Pages
簡介

本報告提供以轉化生長因子-β1 (TGFB1) 為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

轉化生長因子-β1 (TGFB1) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥開發企業

  • Acceleron Pharma, Inc.
  • Digna Biotech, S.L.
  • Dong Wha Pharma Co., Ltd.
  • Eli Lilly and Company
  • Huabo Biopharm Co., Ltd.
  • Isarna Therapeutics GmbH
  • Johnson & Johnson
  • Novartis AG
  • Scholar Rock, Inc.
  • Sirnaomics, Inc.
  • 大正製藥集團
  • TissueGene, Inc.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0443TDB

Summary

Global Markets Direct's, 'Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2016', provides in depth analysis on Transforming Growth Factor Beta 1 (TGFB1) targeted pipeline therapeutics.

The report provides comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)
  • The report reviews Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Transforming Growth Factor Beta 1 (TGFB1) Overview
  • Therapeutics Development
    • Transforming Growth Factor Beta 1 (TGFB1) - Products under Development by Stage of Development
    • Transforming Growth Factor Beta 1 (TGFB1) - Products under Development by Therapy Area
    • Transforming Growth Factor Beta 1 (TGFB1) - Products under Development by Indication
  • Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Transforming Growth Factor Beta 1 (TGFB1) - Products under Development by Companies
  • Transforming Growth Factor Beta 1 (TGFB1) - Products under Development by Universities/Institutes
  • Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Transforming Growth Factor Beta 1 (TGFB1) - Companies Involved in Therapeutics Development
    • Acceleron Pharma, Inc.
    • Digna Biotech, S.L.
    • Dong Wha Pharma Co., Ltd.
    • Eli Lilly and Company
    • Huabo Biopharm Co., Ltd.
    • Isarna Therapeutics GmbH
    • Johnson & Johnson
    • Novartis AG
    • Scholar Rock, Inc.
    • Sirnaomics, Inc.
    • Taisho Pharmaceutical Holdings Co., Ltd.
    • TissueGene, Inc.
  • Transforming Growth Factor Beta 1 (TGFB1) - Drug Profiles
    • ACE-1332 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibody to Inhibit TGF-Beta 1 for Osteoarthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibody to Inhibit TGFB1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • decorin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • disitertide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DW-1029M - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HB-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HB-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISTH-1047 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISTH-1106 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melittin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit TGF Beta 1 for Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Activate TGF beta1 for Autoimmune Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit TGF Beta1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STP-705 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TASP-0382088 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tonogenchoncel-L - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XOMA-089 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Transforming Growth Factor Beta 1 (TGFB1) - Dormant Projects
  • Transforming Growth Factor Beta 1 (TGFB1) - Discontinued Products
  • Transforming Growth Factor Beta 1 (TGFB1) - Featured News & Press Releases
    • Feb 16, 2016: Regenerative Medicine Company, TissueGene, adds Dr. Gurdyal Kalsi as Chief Medical Officer
    • Jul 14, 2015: Scholar Rock Presents Preclinical Data for First Demonstration of Novel Pharmacological Approach to Targeting the TGFß1 Latent Complex
    • May 11, 2015: TissueGene Presents Phase 2 Data for Its Novel Cell Therapy for the Treatment of Osteoarthritis of the Knee
    • Jan 22, 2015: Sirnaomics Files to Begin Trial of Scar-healing Drug in China as it Seeks Funding in US
    • Jan 05, 2015: Sirnaomics and Partner Submit IND to CFDA
    • Nov 17, 2014: TissueGene Receives Recommendations from FDA on Pathway to Phase 3 Trial of TG-C for Treatment of Osteoarthritis of the Knee
    • Nov 14, 2012: TissueGene Completes Enrollment In US Phase II Study Of TG-C In Patients With Knee Osteoarthritis
    • Jun 28, 2012: Sirnaomics Nears Phase I Study of Wound-Healing Drug as It Eyes the microRNA Field
    • Jun 25, 2012: Sirnaomics Receives NIH SBIR Grant For Developing siRNA Therapeutic Product STP705
    • May 19, 2011: TissueGene Initiates Patient Enrollment For Phase II Study Of TG-C For Osteoarthritis Of Knee
    • Mar 25, 2010: Digna Biotech Announced The Results Of Disitertide Proof Of Concept Trial In The Topical Treatment Of Skin Fibrosis
    • Mar 03, 2009: TissueGene Announces Regulatory Allowance To Initiate Phase IIa Study Of TG-C In South Korea For Osteoarthritis Of The Knee
    • Oct 19, 2007: Digna Biotech Biotechnological Company and Isdin Laboratory Begin Phase II Of A Product For Scleroderma
    • Jul 24, 2006: TissueGene Initiates Phase I Clinical Trial with TG-C
    • Apr 19, 2005: RheoGene Inc. And TissueGene Inc. Sign Collaborative Agreement For Bone Regeneration And Repair Program
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Acceleron Pharma, Inc., H2 2016
  • Pipeline by Digna Biotech, S.L., H2 2016
  • Pipeline by Dong Wha Pharma Co., Ltd., H2 2016
  • Pipeline by Eli Lilly and Company, H2 2016
  • Pipeline by Huabo Biopharm Co., Ltd., H2 2016
  • Pipeline by Isarna Therapeutics GmbH, H2 2016
  • Pipeline by Johnson & Johnson, H2 2016
  • Pipeline by Novartis AG, H2 2016
  • Pipeline by Scholar Rock, Inc., H2 2016
  • Pipeline by Sirnaomics, Inc., H2 2016
  • Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016
  • Pipeline by TissueGene, Inc., H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Dormant Projects (Contd..2), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top